How Hospital Profits Drive Oncology Biosimilar Use

How Hospital Profits Drive Oncology Biosimilar Use

The healthcare landscape is witnessing a massive shift due to oncology biosimilar adoption. As biologics lose patent protection, lower-cost alternatives are becoming more prevalent. Consequently, hospitals are re-evaluating their treatment protocols to incorporate these agents. Manufacturers are also lowering acquisition prices to remain competitive in a crowded market. This study investigates how these financial dynamics influence hospital behavior and patient care.

Economics of Oncology Biosimilar Adoption

Furthermore, researchers discovered that drug acquisition prices for major biosimilars fell by up to 72%. Specifically, bevacizumab, trastuzumab, and rituximab saw significant price declines between 2020 and 2024. However, insurer reimbursement rates did not drop at the same pace. Therefore, hospital markup margins for these drugs actually increased over time. This economic incentive proved highly effective at encouraging facilities to switch from original biologics. As a result, utilization rates for these biosimilars climbed from roughly 30% to over 90% in just four years.

Market Trends and Clinical Implications

Additionally, the data suggests that financial gainsharing is a powerful tool for system efficiency. For every dollar reduction in the price hospitals paid, their reimbursement remained robust. This gap allowed hospitals to improve their balance sheets while providing high-quality therapy. Moreover, clinicians in India are increasingly confident in using biosimilars for various cancers. Government initiatives like \”Biopharma SHAKTI\” further support this domestic biopharmaceutical growth. Ultimately, aligning financial incentives with lower-cost therapies benefits both providers and the broader healthcare system.

Frequently Asked Questions

Q1: Why are hospitals adopting oncology biosimilars so quickly?

Hospitals are adopting them because the profit margins have increased. While the price they pay to manufacturers has dropped sharply, the amount they receive from insurers has decreased much more slowly.

Q2: What impact does this have on the overall cost of cancer care?

This trend helps lower the total cost of biologics by fostering competition. When hospitals save money through biosimilars, it encourages a cycle of price reductions across the pharmaceutical market.

References

1. Robinson JC et al. Hospital Adoption and Pricing for Oncology Biosimilars. JAMA. 2026 Mar 11. doi: 10.1001/jama.2026.1777. PMID: 41811336.
2. IMARC Group. India Biosimilar Market Size, Companies and Growth, 2034.
3. Ramesh A. Clinicians’ Perceptions and Adoption of Oncology Biosimilars in India: Results from a National Survey. Ind J Med Paediatr Oncol. 2025 Sep.